Context Therapeutics Inc.
CNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $23 | $18 | $7 | $4 |
| G&A Expenses | $7 | $7 | $8 | $4 |
| SG&A Expenses | $7 | $7 | $8 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $3 |
| Operating Expenses | $30 | $25 | $15 | $11 |
| Operating Income | -$30 | -$25 | -$15 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $1 | $1 | $0 |
| Pre-Tax Income | -$27 | -$24 | -$15 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$24 | -$15 | -$10 |
| % Margin | – | – | – | – |
| EPS | -0.46 | -1.5 | -0.93 | -3.69 |
| % Growth | 69.3% | -61.3% | 74.8% | – |
| EPS Diluted | -0.46 | -1.5 | -0.93 | -3.69 |
| Weighted Avg Shares Out | 58 | 16 | 16 | 3 |
| Weighted Avg Shares Out Dil | 58 | 16 | 16 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$30 | -$25 | -$15 | -$10 |
| % Margin | – | – | – | – |